How MacroGenics Increased mAb Titers By Up To 80% In Scale-Up

Discover how MacroGenics advanced monoclonal antibody development using a platform approach to media and feed optimization. In this case study, the team reported up to 80% higher titers, while maintaining acceptable aggregation and glycosylation profiles, and successfully scaling the process to cGMP manufacturing.

Learn how a structured, scalable approach to process development can help improve productivity, maintain product quality, and support a smoother transition to manufacturing.